Heidi Cuthbert

Sociedad Química y Minera de Chile (NYSE:SQM) reported a sharp rebound in its first-quarter financial results for 2026, driven by an acceleration in electric vehicle battery materials demand that led the producer to raise its full-year delivery guidance.

Trajan Group (ASX:TRJ) confirmed that its operational initiatives remain on track despite shifting macroeconomic conditions and sudden currency volatility.

Biome Australia (ASX:BIO) has launched its multi-centre, international clinical trial for BMB18.

The Federal Court has ordered Westpac (ASX:WBC) to pay a $26 million civil penalty.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) released updated Phase 1/2 clinical data for its experimental antibody-drug conjugate, CRB-701, demonstrating therapeutic activity in patients with pretreated, human papillomavirus (HPV)-associated solid tumors that express high levels of the Nectin-4 protein.

Freightos (NASDAQ:CRGO) reported mixed financial and operational metrics for the first quarter of 2026, as geopolitical tensions and airspace restrictions across the Middle East slowed core transaction growth while simultaneously driving up global shipping rates to support the logistics platform's overall transaction value.

NervGen Pharma (NYSE:NGEN) reported positive results from an independent, blinded biomechanical gait analysis of its Phase 1b/2a CONNECT SCI study, demonstrating that its lead candidate, NVG-291, achieved statistically significant improvements in walking quality among chronic spinal cord injury patients.

Champion Homes (NYSE:SKY) entered into a definitive agreement to acquire the retail assets of Homes Direct, securing 11 high-volume sales locations to accelerate its direct-to-consumer distribution strategy across the Western U.S.

Kura Oncology (NASDAQ:KURA) reported preliminary Phase 1a data from its FIT-001 clinical trial, showing that a combination of its next-generation farnesyl transferase inhibitor darlifarnib and adagrasib induced tumor shrinkage in 77% of evaluable patients with advanced solid tumors.

Yatsen Holding (NYSE:YSG) reported a 22.5% increase in first-quarter revenue, driven by accelerating consumer demand for its skincare portfolio, though aggressive promotional spending and higher research outlays widened its net loss.